Mainstream

Novo Nordisk Says Higher Wegovy Dose Caused Over 20% Weight Loss In Late Stage Trial

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Post Contentnvo, llyRead More

You might also be interested in reading Oscar Health outlines $12B–$12.2B 2025 revenue target and new ICHRA strategy amid market reset.

January 17, 2025
In Mainstream